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Original ArticleAMPK activation negatively regulates GDAP1,
which inﬂuences metabolic processes and
circadian gene expression in skeletal muscleDavid G. Lassiter 1, Rasmus J.O. Sjögren 1, Brendan M. Gabriel 2, Anna Krook 2, Juleen R. Zierath 1,2,3,*ABSTRACT
Objective: We sought to identify AMPK-regulated genes via bioinformatic analysis of microarray data generated from skeletal muscle of animal
models with genetically altered AMPK activity. We hypothesized that such genes would play a role in metabolism. Ganglioside-induced differ-
entiation-associated protein 1 (GDAP1), a gene which plays a role in mitochondrial ﬁssion and peroxisomal function in neuronal cells but whose
function in skeletal muscle is undescribed, was identiﬁed and further validated. AMPK activation reduced GDAP1 expression in skeletal muscle.
GDAP1 expression was elevated in skeletal muscle from type 2 diabetic patients but decreased after acute exercise.
Methods: The metabolic impact of GDAP1 silencing was determined in primary skeletal muscle cells via siRNA-transfections. Confocal mi-
croscopy was used to visualize whether silencing GDAP1 impacted mitochondrial network morphology and membrane potential.
Results: GDAP1 silencing increased mitochondrial protein abundance, decreased palmitate oxidation, and decreased non-mitochondrial
respiration. Mitochondrial morphology was unaltered by GDAP1 silencing. GDAP1 silencing and treatment of cells with AMPK agonists altered
several genes in the core molecular clock machinery.
Conclusion: We describe a role for GDAP1 in regulating mitochondrial proteins, circadian genes, and metabolic ﬂux in skeletal muscle.
Collectively, our results implicate GDAP1 in the circadian control of metabolism.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords AMPK; Skeletal muscle; GDAP1; Diabetes; Circadian; MitochondriaSkeletal muscle is a major regulator of whole-body metabolic ho-
meostasis. AMP-activated protein kinase (AMPK) is of particular
importance for metabolic regulation in skeletal muscle given its role in
glucose transporter type 4 (GLUT4)-mediated glucose uptake, inhibi-
tion of fatty-acid synthesis, and activation of mitochondrial biogenesis
[1]. Importantly, skeletal muscle of type 2 diabetic patients retains the
ability to activate AMPK during exercise, despite exhibiting several
metabolic deﬁciencies, including impaired insulin-stimulated glucose
uptake [2]. This is of clinical relevance given that prescriptions of
lifestyle interventions, which include regular exercise training, have
been reported to be as good as, or superior to, pharmacological
treatment to preventing the development of type 2 diabetes in at-risk
individuals [3,4]. To gain insight into mechanisms by which AMPK
modiﬁes metabolic health, we have developed several genetically-
modiﬁed animal models, which exhibit enhanced or diminished
AMPK-mediated phosphorylation [5].
Skeletal muscle of mice with chronically activated AMPK activity exhibit
a differential gene expression proﬁle, which opposes that of mice with
chronically impaired AMPK activity [6]. Pharmacological treatment of
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expression of oxidative genes in gastrocnemius muscle [7], implicating
AMPK as a direct regulator of gene expression. Supporting evidence for
AMPK as a transcriptional regulator comes from the ﬁndings that its
catalytic subunit contains a nuclear export sequence, and its phos-
phorylation targets include cytoplasmic and nuclear proteins [8,9].
Although microarray studies demonstrate that AMPK modulates the
expression of speciﬁc candidate genes, these putative AMPK-
dependent genes have not been independently validated for a role in
metabolic homeostasis.
Transcriptomic studies reveal that ganglioside-induced differentia-
tion-associated protein 1 (GDAP1) mRNA is inversely associated with
AMPK activity [6,7]. GDAP1 encodes for ganglioside-induced differ-
entiation-associated protein 1 (GDAP1) [6,7]. Mutations in GDAP1
lead to an incurable neurological disorder, Charcot-Marie Tooth
disease, which is characterized by altered mitochondrial morphology
[10,11]. GDAP1 may be autoinhibitory, playing a role in mitochondrial
ﬁssion in its active conformation [12]. GDAP1 is linked to insulin
signaling and altered substrate handling of carbohydrates and lipids
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function of mitochondria are subject to disruption by improper GDAP1
expression, and that GDAP1 expression is under the control of AMPK,
we hypothesized that GDAP1 plays a role in skeletal muscle
metabolism.
In this study, we ﬁrst utilized publically-available transcriptomics data
from rodent models of altered AMPK activation in skeletal muscle to
identify novel AMPK-regulated gene candidates for further validation in
the context of metabolic homeostasis. Speciﬁcally, we compared the
skeletal muscle transcriptomic proﬁles of AMPKg3R225Q transgenic
mice, AMPKg3/ knockout mice, and AICAR-treated wild-type mice.
We have previously reported evidence for AMPKg3-dependent tran-
scriptional regulation in skeletal muscle [6]. Additionally, we have
shown that phosphorylation of the AMPK target ACC is increased in
skeletal muscle of AMPKg3R225Q transgenic mice under basal condi-
tions and in response to either AICAR-stimulated or exercise compared
with wild-type mice, and unaltered between AMPKg3/ knockout
and wild-type mice [5,14]. These genetically modiﬁed mouse models
have been useful to identify AMPKg3-dependent gene transcription
and metabolic regulation. In terms of the AMPKg3/ mouse model,
despite a relatively low contribution to global AMPK activity, the g3 unit
may have very speciﬁc and important inﬂuences on the outcomes of
AMPK activation. Thereafter, we validated the role of one such
candidate gene, GDAP1, in skeletal muscle metabolism. Our approach
identiﬁes GDAP1 as a novel AMPK target that plays a role in metabolic
processes and circadian gene expression in skeletal muscle.
1. METHODS
1.1. Bioinformatic analysis
To identify candidate genes regulated by AMPK activity in skeletal
muscle, microarray data were downloaded from the Gene Expression
Omnibus (GEO) corresponding to models wherein AMPK activity was
experimentally increased (GSE11804 and GSE4065) or decreased
(GSE4063). Data from GSE11804 compared mice injected for six days
with AICAR to saline-injected control mice [6]. Data from GSE4065 and
GSE4063 compared wild-type littermates to either AMPKg3R225Q or
AMPKg3/ mice, representing gain or loss of AMPK function
respectively [7]. All data were preprocessed by the robust multi-array
average method [15] then non-annotated genes were ﬁltered out, and
unpaired t-tests were used with a ¼ 0.05 to determine which tran-
scripts were differentially expressed in each of the three cohorts. To
identify AMPK-regulated genes, gene sets from each of the cohorts
were further ﬁltered to include only genes which were either 1)
upregulated in both models of AMPK activation and downregulated in a
model of AMPK inhibition, or 2) downregulated in both models of AMPK
activation and upregulated in a model of AMPK inhibition.
1.2. AMPKg3/ and AMPKg3R225Q mice
Skeletal muscle was harvested from male AMPKg3/ or
AMPKg3R225Q mice (both generated on a C57BL/6 background) and
wild-type littermates, generated as described [5]. Animals were
housed with same sex littermates in groups of 2e4 mice in cages with
wood-chip bedding, clumps of tissue paper, and a cardboard shelter.
The researchers handling the animals were blinded to the genotype.
Mice were either starved for 12 h or had ad libitum access to food
before being anesthetized with tribromoethanol. Thereafter, tissues
were collected and frozen with clamps pre-cooled in liquid nitrogen.
mRNA was extracted and converted to cDNA from gastrocnemius
muscle as described [16]. Animal research was approved under li-
cense number N263/12 by the local ethical committee, the Stockholm
North Animal Research Ethics Committee.MOLECULAR METABOLISM 16 (2018) 12e23  2018 The Authors. Published by Elsevier GmbH. This is an open ac
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Skeletal muscle cDNA from a previously published cohort of type 2
diabetes patients and normal glucose tolerant age-matched controls
was used in this study [17]. The clinical characteristics of the study
participants have been previously reported [17]. These participants
donated skeletal muscle biopsies at three timepoints: at rest, imme-
diately after 30 min of cycle ergometry at 85% of maximum heart rate,
and 3 h after the exercise bout. Muscle biopsies were homogenized,
RNA isolated, and converted to cDNA in a reverse transcription reac-
tion, as described [17]. Muscle biopsies were also obtained from
fasted normal glucose tolerant volunteers and primary cultures were
prepared as described [16,18,19]. Informed consent was received
from all study participants. The experimental procedures were con-
ducted according to the Declaration of Helsinki and approved under the
license number 2005/1080-31/4 by the local ethical committee for the
participants who served as donors for the primary human skeletal
muscle cells and under the license number 2013/647-31/3 for the
participants who donated skeletal muscle biopsies.
1.4. Growth, differentiation, and siRNA-transfection in primary
human skeletal muscle cells
Cells were grown and differentiated as previously described
[16,18,19]. In one experiment, cells were differentiated then treated
with 0.5 mM AICAR for 24 h prior to being harvested to interrogate
gene expression. For one circadian experiment, skeletal muscle
myotubes were differentiated into myotubes and then incubated with
differentiation medium with 50% horse serum for 2 h before
replacement with normal media to induce circadian gene oscillations,
as previously described [20]. In all other experiments, cells were
studied after being transfected to silence GDAP1 gene expression. In
an initial experiment to interrogate if transfection with siRNA against
GDAP1 would reduce protein abundance of GDAP1, cells were har-
vested 48 h after a single transfection, or after two transfections
separated by 48 h. After determining that protein abundance had the
greatest reduction after two transfections separated by 48 h (thus, 96 h
after the ﬁrst transfection), the same transfection timing was used for
all other experiments. The transfection methods employed have been
described earlier [19], using 5 mM of either silencer select Negative
control No.2 (no. 4390847) or validated silencer select siRNA s28923
to target GDAP1 for two separate 5-h transfection periods separated by
w48 h (Thermo Fisher Scientiﬁc, Waltham, MA). Two days after the
ﬁnal transfection, primary human skeletal muscle cells used to eval-
uate gene expression, protein signaling, metabolic function, or mito-
chondrial morphology.
1.5. GDAP1 silencing and AMPK-agonist treatment in primary
human skeletal muscle cells
In the experiments performed using siRNA-transfections, the cells
were treated for 48 h with either of the AMPK-activating compounds,
0.5 mM AICAR or 0.125 mM phenformin. Cells were subsequently
harvested for gene expression analysis via RT-qPCR or protein
signaling by western blot analysis as described [16].
1.6. Metabolic phenotyping of cells after GDAP1 silencing
Palmitate oxidation in primary human skeletal muscle cells was
analyzed by exposing cells to 0e5 g glucose/L media for 6 h in the
presence of radiolabeled palmitate (9, 10-[3H]palmitate,
NET043005MC; PerkinElmer, Waltham, MA) as described [16]. The
supernatant was subsequently processed and subjected to scintillation
counting, and data were normalized to the protein content (Protein
Assay Dye Reagent #5000006; Bio-Rad, Hercules, CA).cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 13
Table 1 e Oligonucleotides used in the qPCR analysis.
Gene Forward Primer Reverse Primer
Mm_B2m TGCTATCCAGAAAACCCCTCA GGGTGAATTCAGTGTGAGCC
Mm_Gdap1 GGTCTTGGATCAGGTGGAAA GATGCAATGTGACAGCCAGT
Hs_B2M TGTCTTTCAGCAAGGACTGG AGCAAGCAAGCAGAATTTGG
Hs_TBP AGTTCTGGGATTGTACCGCA TATATTCGGCGTTTCGGGCA
Hs_TFRC CTGCAAAATCCGGTGTAGGC TGAAGTTGCTGGTACCAAGAAC
Hs_RPLP0 AGATTCGGGATATGCTGTTGGC TCGGGTCCTAGACCAGTGTTC
Hs_GDAP1 TGGAGAAAGTCTTGGATCAGGT CTGCCAGGGTGAAGGATTC
Hs_DES GGCTACCAGGACAACATTGC GATTGATCCGGCTCTCCTCT
Hs_PDK4 CACAGACAGGAAACCCAAGC GCCCGCATTGCATTCTTAAA
Hs_DNM1L TGGTGAAGCGGCAAATCAAA TGCCACTAAGTTATGGACCATT
Hs_FIS1 CAGTTTGAGTACGCCTGGTG TCTCGTATTCCTTGAGCCGG
Hs_MFN2 GAACTGTCTGGGACCTTTGC CCAACCGGCTTTATTCCTGAG
Hs_MARCH5 GTGACAGTGATGCAGGTTGT TTCGAGTATTTGCGCCACAG
Hs_NR1D2 TGGAGTTCATGCTTGCGAAG ACCAAACCGAACAGCATCTC
Hs_PER3 AGCCTTACAAGCTGGTTTGC GTAGCATCCCTGGCTGTCTC
Hs_NPAS2 TGAATCTGACCACACCTGCT CTCTGGGCGTACTTGACTTG
Hs_DBP CCCAGCTGATCTTGCCCTAT GGCTCCAGTATTTCTCATCCTTC
Original ArticleGlucose oxidation and glycogen synthesis were assayed as described
[16,19]. Cells were subjected to a 5-h serum starvation prior to
exposure to insulin (10 or 120 nM) and radiolabeled glucose (D-[U-14C]
glucose, NEC042B005MC; PerkinElmer). In the glycogen synthesis
assay, cells were exposed to insulin and radiolabeled glucose for 2 h,
then harvested, processed, and subjected to scintillation counting. In
the glucose oxidation assay, cells were exposed to insulin and radio-
labeled glucose for 4 h in air-tight cell-culture wells prior to an addition
of 150 mL 2 M HCl; for 1 h. The CO2 released from this reaction was
collected into small cups in the cell-culture wells containing 300 mL of
2 M NaOH prior to being subjected to scintillation counting. In both
assays, radioactive counts were normalized to protein content,
quantiﬁed by a Bradford colorometric assay (Bio-Rad).
Glucose uptake in primary human skeletal muscle cells was assessed
by exposing cells to 2-[1,2-3H]deoxy-D-glucose, as described [19].
Cells were processed and subjected to scintillation counting. To
analyze lactate production, media was collected from the same cells
prior to exposure to the radiolabeled glucose. Lactate was measured in
a colorimetric assay using N-methylphenazonium methyl sulphate,
iodonitrotetrazolium chloride, lactic acid, b-nicotinamide adenine
dinucleotide hydrate, and lactate dehydrogenase [21] (SigmaeAldrich,
St. Louis, MO). Radioactive counts corresponding to glucose uptake
and lactate measured by the colorimetric assay were normalized to
protein quantiﬁed by a Bradford colorometric assay (Bio-Rad).
To assess the mitochondrial function of primary human skeletal
muscle cells after GDAP1 silencing, cells were subjected to a Seahorse
XF Mito Stress Test using the manufacturer’s instructions for timing
(Agilent, Santa Clara, CA). Oxygen consumption rates (OCR) and
extracellular acidiﬁcation rates (ECAR) were measured at three time-
points under unstimulated conditions, then after treatment with 1 mM
oligomycin, 2 mM FCCP, and 0.75 mM rotenone þ antimycin A. OCR
and ECAR were normalized to protein as quantiﬁed by a Pierce BCA
protein assay kit (Thermo Fisher Scientiﬁc).
1.7. Mitochondrial morphology with confocal microscopy
Mitochondrial morphology was examined using confocal microscopy
(LSM880, Carl Zeiss AG, Jena, Germany) after staining cells with
ViaFluor SE (Biotium Inc., Fremont, CA), Hoechst dye, and MitoTracker
Deep Red (Thermo Fisher Scientiﬁc) according to manufacturer’s in-
structions. Images from elongated multinucleated cells were captured
using a 40x-objective on a confocal microscope. Mitochondrial net-
works were qualitatively assessed by researchers who were blinded to
the treatment conditions. Additionally, images were quantiﬁed via
Mitochondrial Network Analysis (MiNA) toolset and ImageJ [22].
1.8. Gene expression analysis
cDNA was prepared from human skeletal muscle, AMPKg3/ mice,
and primary human skeletal muscle cells. Gene expression was
determined by using Fast SYBR Green Master Mix (Thermo Fisher
Scientiﬁc) and self-designed oligonucleotides (oligonucleotide se-
quences provided in Table 1).
1.9. Protein abundance in primary human skeletal muscle cells
Cells were scraped into lysis buffer, supernatants were centrifuged,
and the protein concentration was quantiﬁed by a Pierce protein assay
kit (Thermo Fisher Scientiﬁc). Samples were diluted in Laemmli buffer
to equal protein concentration prior to being subjected to western blot
analysis as described [16]. Commercially available antibodies including
p-ACC2S222 (#3661) and ACC (#3676) from Cell Signaling Technology
(Beverly, MA), MYH1/2 (#sc-53088) from Santa Cruz Biotechnology
(Dallas, TX), Desmin (#ab15200) and Total OXPHOS (#110411) from14 MOLECULAR METABOLISM 16 (2018) 12e23  2018 The Authors. Published by Elsevier GmbH. TAbcam (Cambridge, UK), GDAP1 (#H00054332-A01) from Abnova
(Taipei, Taiwan), and b-actin (#A5441) from SigmaeAldrich were used
for western-blot analysis. GDAP1 (#H00054332-A01) from Abnova
(Taipei, Taiwan) was optimized for human skeletal muscle cells, but
we were unable to optimize this antibody in mouse skeletal muscle.
1.10. Experimental outcomes
Gene expression of GDAP1 was the primary experimental outcome to
validate the bioinformatics analysis. After validating that GDAP1 mRNA
is negatively regulated by AMPK activity, secondary experimental
outcomes included assessing the effects of GDAP1 silencing on the
expression of metabolic genes, abundance of mitochondrial proteins,
and metabolic phenotyping via assays of palmitate oxidation, lactate
production, glucose uptake, glycogen synthesis, glucose oxidation, and
Seahorse readings. Tertiary experimental outcomes were assessments
of mitochondrial function via the Seahorse assays and morphology as
indicated by confocal microscopy.
1.11. Statistical analysis
When the underlying assumptions were not violated, parametric tests
were utilized to make statistical inferences. When assumptions were
violated, nonparametric tests were used. The omnibus tests applied to
interrogate that data are indicated in respective ﬁgure legends. The
Benjamini-Hochberg false-discovery rate correction method was used
in all post hoc pairwise-comparisons, except in the analysis of the
microarray data for identiﬁcation of candidate genes. The threshold for
signiﬁcance (a) was set to 0.05. R base v 3.4.3 and open-source
packages were used for inferential statistics, while Graphpad Prism
v7.04 (La Jolla, CA) was used for generation of ﬁgures. All data points
are shown in ﬁgures.
2. RESULTS
2.1. Identiﬁcation and validation of GDAP1 as an AMPK-regulated
gene
By overlaying the signiﬁcantly regulated genes from the three GSE
datasets, we identiﬁed 11 candidate genes which were either upre-
gulated (Lpin1, Ugp2, Gpx3, Phlda3) or downregulated (Hhatl, Fam20c,
Kansl1l, Dpp8, Gdap1, Aamdc, Asph) respectively, due to AMPK ac-
tivity (Figure 1A and Table 2). Of these candidate genes, Gdap1 was
selected for further validation. Gdap1 is a known regulator of mito-
chondrial dynamics in neuronal tissue, and mutations of the gene leadhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Identiﬁcation of GDAP1 as an AMPK-regulated gene in skeletal muscle. (A) Venn diagram illustrating the number of signiﬁcantly regulated genes due to increased
AMPK activation (shaded circles) or decreased AMPK activation (empty circle). (B) Blood glucose, (C) mRNA of Gdap1 normalized to B2m in gastrocnemius muscle, (D) bodyweight,
and (E) age of AMPKg3 KO mice (KOko), wild-type littermates (KOwt), AMPKR225Q mice (RQrq), and wild-type littermates (RQwt) under fed (full circles) or fasted (empty boxes)
conditions. All data are plotted from n ¼ 4e7 mice per group. (F) mRNA of GDAP1 in primary human skeletal muscle cells. Expression was normalized to the geometric mean of
B2M, TBP, and RPLP0. All data are plotted from n ¼ 4 matched samples. (G) mRNA of GDAP1 in vastus lateralis muscle from individuals with normal glucose tolerance (NGT) or
type-2 diabetes (T2D) at rest (open circles), 0-h post exercise (ﬁlled diamonds), or 3-h post exercise (empty triangles). Expression was normalized to B2M. All data are plotted from
n ¼ 11e12 per group. *Signiﬁcant pairwise difference between subsets of data indicated by brackets as detected by paired-t test (panel C only) or pairwise post hoc tests after
FDR-correction, ySigniﬁcant effect of treatment as detected by 2-way Independent ANOVA. zSigniﬁcant effect of genotype as detected by 2-way Independent ANOVA. xSigniﬁcant
difference between the groups as detected by KruskaleWallis test (assumptions for 2-way ANOVA were not met).
Q
Signiﬁcant condition-by-time interaction as detected by 2-way
mixed-model ANOVA.
MOLECULAR METABOLISM 16 (2018) 12e23  2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
15
Table 2 e Candidate genes identiﬁed by bioinformatics analysis.
Gene ID GSE4063
AMPKg3/
GSE4065
AMPKg3R225Q
GSE11804
AICAR-treated
Fold-change p-value Fold-change p-value Fold-change p-value
Hhatl 1.23 0.017 1.25 0.034 1.11 0.043
Fam20c 1.20 0.006 1.13 0.001 1.35 0.009
Kansl1l 1.19 0.046 1.37 <0.001 1.09 0.001
Dpp8 1.17 0.021 1.15 0.048 1.23 0.014
Gdap1 1.17 0.020 1.29 0.002 1.29 0.046
Aamdc 1.13 0.012 1.31 0.019 1.11 0.039
Asph 1.10 0.027 1.15 0.005 1.08 0.027
Lpin1 1.19 0.006 1.16 0.014 1.33 <0.001
Ugp2 1.20 0.003 1.32 <0.001 1.16 0.004
Gpx3 1.26 0.017 2.24 <0.001 1.21 0.015
Phlda3 1.36 0.016 1.19 0.005 1.33 0.010
Data were collected from a public repository and processed as described in the
methods. The eleven genes are presented with their gene ID, fold-change as
compared to the control in the respective dataset, and p-value after unpaired t-tests
were performed.
Original Articleto Charcot-Marie Tooth diseases, a motor and sensory neuropathy
affecting 1/2500 people [23].
To validate the ﬁndings from the bioinformatic analysis, Gdap1
expression was assessed in gastrocnemius muscle of AMPKg3/
and AMPKR225Q mice. Blood glucose was reduced in mice subjected to
a 12-h fast (Figure 1B), and GDAP1 expression was inversely related to
AMPK activity (Figure 1C). Gdap1 expression was reduced in skeletal
muscle of mice with constitutively active AMPKg3 (AMPKR225Q mice)
as compared to wild-type littermates. Two minor caveats to this ﬁnding
are that bodyweight was different due to genotype, but no pairwise
comparisons were signiﬁcantly different (Figure 1D), and the fasted
AMPKR225Q mice were older than fed counterparts and fasted wild-type
controls (Figure 1E).
To investigate if GDAP1 expression was directly reduced by AMPK
activation, differentiated primary human skeletal muscle cells were
treated with 0.5 mM AICAR, for 24 h. According to MIT assays, cell
viability was unaffected. GDAP1 expression was reduced in cells
treated with AICAR as compared to untreated control cells (Figure 1F).
Furthermore, GDAP1 expression was elevated at baseline in vastus
lateralis from type 2 diabetic patients but decreased in response to an
acute exercise bout (Figure 1G).
2.2. Effects of GDAP1 silencing on gene expression and protein
abundance
After validating that GDAP1 is expressed in primary human skeletal
muscle cells and directly regulated by AMPK activity, we performed
siRNA-mediated gene silencing of GDAP1 to interrogate the effects on
gene expression and protein abundance. In conjunction with the gene-
silencing experiments, cells were treated with or without the AMPK
activators AICAR (0.5 mM) or phenformin (0.125 mM). The transfection
procedure achieved consistent reductions of GDAP1 expression
(Figure 2A,L). We conﬁrmed our initial ﬁnding that AICAR-treatment
reduces GDAP1 expression, although phenformin had no effect. DES
expression was not altered due to GDAP1 silencing in any of the
treatments, indicating that differentiation was unaltered due to GDAP1
silencing (Figure 2B). AMPK agonists increased PDK4 expression,
although no pairwise comparisons were signiﬁcant, and there was no
effect of GDAP1 silencing (Figure 2C). Several genes which encode
proteins responsible for maintenance of mitochondrial morphology
were increased due to AICAR-treatment including DNM1L, FIS1, and
MFN2, but neither phenformin treatment nor GDAP1 silencing altered16 MOLECULAR METABOLISM 16 (2018) 12e23  2018 The Authors. Published by Elsevier GmbH. Tthe expression of these genes (Figure 2DeF). MARCH5, another gene
involved in mitochondrial morphology, was increased in response to
AICAR treatment and GDAP1 silencing (Figure 2G). The circadian gene
NPAS2 was also increased due to GDAP1 silencing, but unaffected by
AMPK agonists (Figure 2H). In contrast, the circadian gene DBP was
reduced by GDAP1 silencing and increased due to phenformin treat-
ment (Figure 2I). Two other circadian genes, NR1D2 and PER3, showed
altered expression in response to AMPK agonists, but were unaffected
by GDAP1 silencing (Figure 2JeK). Given these effects on circadian
genes, we assessed whether GDAP1 had circadian oscillations in
cultured skeletal muscle cells after serum shock (this induces core-
clock oscillation as previously described [20]) (Figure 2M). GDAP1
gene expression had values of 0 for circadian oscillatory amplitude and
period length after serum shock, when assessed by JTK_CYCLE, a
non-parametric algorithm for detecting rhythmic components [24].
We next investigated whether AMPK activation and GDAP1 silencing
altered the abundance of various proteins involved in metabolism.
Treatment of cells with AICAR or phenformin increased phosphorylated
acetyl CoA carboxylase (ACC), p-ACC2S222, without altering total ACC2
(Figure 3AeB). Myosin heavy-chain was reduced in AICAR-treated
cells (Figure 3C). There was a tendency for GDAP1 silencing to
reduce desmin protein abundance, but post hoc pairwise comparisons
did not reveal a signiﬁcant difference (Figure 3D). The abundance of
mitochondrial complexes V and III were increased by GDAP1 silencing
(Figure 3EeF). Mitochondrial complex II abundance was altered due to
treatment AMPK-agonist treatment, but no pairwise post hoc com-
parisons were signiﬁcant (Figure 3G). Mitochondrial complexes IV and
I, as well as abundance of the reference protein b-actin, were unal-
tered by GDAP1 silencing or AMPK agonists, (Figure 3HeJ).
2.3. Metabolic phenotype of GDAP1-deﬁcient human skeletal
muscle cells
We next determined the inﬂuence of GDAP1 on glucose and lipid
metabolism in cultured human skeletal muscle cells. Following GDAP1
silencing, cells were incubated in 0e5 g/L glucose. GDAP1 silencing
reduced lipid oxidation of skeletal muscle cells, speciﬁcally in the
presence of 1 g/L glucose (Figure 4A). However, we were unable to
detect differences in glucose oxidation or glycogen synthesis in the
presence or absence of insulin in GDAP1-silenced cells (Figure 4BeC).
Furthermore, lactate production and glucose uptake was unaltered by
GDAP1 silencing (Figure 4DeE).
To further investigate the metabolic role of GDAP1, cells were sub-
jected to a Seahorse XF Mito Stress Test. While the sequential addition
of oligomycin, FCCP, and rotenone þ antimycin A altered OCR and
ECAR, GDAP1 silencing was without effect (Figure 5AeB). A beneﬁt of
using the Seahorse Mito Stress test to investigate OCR and ECAR is
that it permits the calculation of various metabolic parameters by
comparing the responses of cells at different timepoints and under
different pharmacological stimuli. We found that non-mitochondrial
respiration was decreased by GDAP1 silencing (Figure 5C). However,
other metabolic parameters including basal respiration, ATP produc-
tion, proton leak, maximal respiration, oxidative spare capacity,
coupling efﬁciency, non-glycolytic acidiﬁcation, and glycolytic capacity
were unaffected by GDAP1 silencing (Figure 5DeK).
2.4. Effect of GDAP1 silencing on mitochondrial morphology in
primary human myotubes
Morphology of mitochondrial networks in primary human myotubes
was unaltered by GDAP1 silencing (Figure 6AeB). Although individual
images of single myotubes under any given condition may have
appeared to have more punctated mitochondrial or more robusthis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: GDAP1 silencing in primary human skeletal muscle cells affects
MARCH5, NPAS2, and DBP mRNA expression. Primary human skeletal muscle cells
were used for qPCR analysis of gene expression after normalization to the geometric
mean of B2M and TFRC. Cells were transfected with a non-targeting scrambled control
MOLECULAR METABOLISM 16 (2018) 12e23  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comnetworks, these observations were not consistent between the treat-
ment groups. Additionally, quantitative analysis via MiNA toolset [22]
identiﬁed no statistical differences in mitochondrial network size,
amount or branch length (Table 3).
3. DISCUSSION
AMPK plays an indirect role in regulating the gene expression proﬁle of
skeletal muscle via interactions with p53, Class IIA histone deacety-
lases (HDACs), peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1a), cAMP-response-element binding pro-
tein (CREB) family proteins, forkhead box protein O (FoxO) family
proteins, and transcriptional regulators [25]. Our research adds to the
understanding of the role of AMPK in metabolic regulation by over-
laying results from microarray studies to identify novel AMPK-
dependent candidate genes in skeletal muscle. Several of these
AMPK-regulated genes warrant further investigation including adipo-
genesis associated Mth938 domain-containing protein (AAMDC),
aspartate beta-hyroxylase (ASPH), dipeptidyl peptidase 8 (DPP8), KAT8
regulatory NSL complex subunit 1 like (KANSL1L), and lipin 1 (LPIN1).
Since DPP8 is closely related to DPP4, a pharmacological target for the
treatment of type 2 diabetes, and LPIN1 has been linked to AMPK
activity in rodent liver’s subjected to metabolic stress [26], these
targets warrant special attention for future studies.
Here we interrogated the role of GDAP1 in the regulation of meta-
bolism in skeletal muscle. Using AMPKg3 subunit transgenic and
knockout mouse models and primary human muscle cells, we
demonstrate that AMPK activity is inversely coupled to GDAP1 gene
expression, indicative of AMPK regulation. We also provide evidence
that GDAP1 expression is elevated in vastus lateralis muscle of type
2 diabetic patients and reduced 3-h after an acute exercise bout.
Our ﬁndings couple AMPK activity to the level of GDAP1 gene
expression, and provide novel evidence for a role of this gene in
skeletal muscle metabolism. The precise link between AMPK activity
and GDAP1 regulation is unknown. YY1 may transcriptionally
regulate GDAP1 via a functional binding site in GDAP1’s core pro-
moter [27]. In turn, YY1 is regulated by PGC-1a [28], this may be the
indirect mechanism by which AMPK regulates GDAP1 [29]. GDAP1
has mainly been studied in neuronal development and dysfunction.
Given that GDAP1/ mice have enlarged neuronal mitochondria,
GDAP1 protein has been implicated in mitochondrial division
[30,31]. The muscular dysfunction and eventual atrophy exhibited in
GDAP1/ mice and patients with Charcot-Marie Tooth disease
have classically been attributed to a secondary functional loss at the
neuromuscular junctions as a consequence of disruption of the
axonal arms in peripheral nerves.RNA (open squares) or siRNA targeted against GDAP1 (black circles) and treated with
regular media (Unt), AICAR (AIC), or phenformin (Phen). Individual graphs report results
for (A) GDAP1, (B) DES, (C) PDK4, (D) DNM1L, (E) FIS1, (F) MFN2, (G) MARCH5, (H)
NPAS2, (I) DBP, (J) NR1D2, and (K) DBP expression. (L) GDAP1 protein 48 h after a
single transfection (48 h) or after two transfections separated by 48 h (96 h). (M)
GDAP1 expression after serum shock to induce circadian oscillations in primary human
skeletal muscle cells. All data are plotted from n ¼ 7 matched samples (AeK) or n ¼ 3
matched samples (L). *Signiﬁcant pairwise difference between subsets of data indi-
cated by brackets as detected by pairwise post hoc tests after FDR-correction.
ySigniﬁcant differences among groups as detected by Friedman’s test (assumptions
for 2-way-RM ANOVA were not met). zSigniﬁcant effect of pharmacological treatment
as detected by 2-way-RM ANOVA. xSigniﬁcant effect of GDAP1 silencing as detected by
2-way-RM ANOVA.
Q
Signiﬁcant treatment-by-time interaction as detected by 2-way-
RM ANOVA.
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Figure 3: GDAP1 silencing increases mitochondrial proteins for Complex V and
II. Primary human skeletal muscle cells were used for western blot analysis of protein
abundance. Cells were transfected with a non-targeting scrambled control RNA (open
Original Article
18 MOLECULAR METABOLISM 16 (2018) 12e23  2018 The Authors. Published by Elsevier GmbH. TWe next assessed the effect of GDAP1 knockdown on mitochondrial
form or function in skeletal muscle. Despite an increase in mito-
chondrial complex proteins, GDAP1 silencing reduced lipid oxidation
in primary human muscle. GDAP1 silencing reduced non-
mitochondrial respiration, suggesting alterations in peroxisomal
function. Effective peroxisomal processing of acyl chains alleviates
some of the metabolic burden caused by obesity and insulin resis-
tance [32]. Moreover, impaired mitochondrial fatty-acid oxidation can
be compensated for by increased peroxisomal oxidation [33].
Although GDAP1 is localized to the mitochondria, GDAP1 knockdown
reduced peroxisomal fragmentation [34]. Our data may be explained
by a potential cell-speciﬁc role of GDAP1, wherein it primarily reg-
ulates mitochondrial ﬁssion in nerve cells, and is delegated to
peroxisomal regulation in skeletal muscle. Thus, it is perhaps un-
surprising that we failed to detect robust alterations in mitochondrial
morphology or mitochondrial function due to GDAP1 silencing. A
“peroxisome-centric” role of GDAP1 in skeletal muscle may also
explain why GDAP1 silencing did not alter the other metabolic pa-
rameters investigated herein.
Disruptions in GDAP1 may perturb whole-body metabolism. Genome-
wide association studies (GWAS) compiled in the new GWAS catalog
link GDAP1 to various symptoms of metabolic disorder [35]. Specif-
ically, single-nucleotide polymorphisms (SNPs) in GDAP1 associate
with waist circumference [36e43], cholesterol, body-fat distribution,
BMI, triglycerides, and blood pressure [44], and obesity-related traits
such as BMI, fatty acids, metabolic rate, and sleep [36,45e47]. Our
ﬁndings coincide with the GWAS data in that GDAP1 knockdown
reduced palmitate oxidation in skeletal muscle, which may lead to an
increased risk of metabolic derangement through the accumulation of
intramuscular lipid species, including diacylglycerols and ceramides
[48,49].
Given that GDAP1 mutations cause neurological disorder and SNPs in
the gene associate with aspects of the metabolic syndrome, the tele-
ological conundrum remains as to why AMPK activation reduces GDAP1
expression. We initiated our research by identifying a relationship be-
tween AMPK activation and GDAP1 expression. However, we extended
our ﬁndings to several models including mice with differing levels of
AMPK activity, primary human skeletal muscle cells treated with AICAR
and studies in patients with type 2 diabetes. Furthermore, using the
gene expression omnibus (GEO) [50], we observed that GDAP1
expression in gastrocnemius muscle from mice is responsive to a 12 h
fast [51] or lifelong caloric restriction [52]. Collectively, these data
support our hypothesis that downregulation of GDAP1 expression by
AMPK activation may be an adaptive response to metabolic stress given
that AMPK activation is an acute event that prioritizes cell energy uti-
lization towards rapid ATP production. Although chronic disruption of
GDAP1 has negative consequences for mitochondrial and peroxisomal
function, a temporary impairment of translation of the GDAP1 gene by
AMPK activity is unlikely to produce long-term negative outcomes, and
in type 2 diabetes, it may even be beneﬁcial.squares) or siRNA targeted against GDAP1 (black circles) and treated with regular
media (Unt), AICAR (AIC), or phenformin (Phen). (A) p-ACC2S222. (B) ACC2. (C) MYH1/2.
(D) Desmin. (E) OXPHOS Complex V. (F) OXPHOS Complex III. (G) OXPHOS Complex II.
(H) OXPHOS Complex IV. (I) OXPHOS Complex I. (J) b-Actin. All data are plotted from
n ¼ 7e8 matched samples. *Signiﬁcant pairwise difference between subsets of data
indicated by brackets as detected by pairwise post hoc tests after FDR-correction,
ySigniﬁcant differences among groups as detected by Friedman’s test (assumptions
for 2-way-RM ANOVA were not met), zSigniﬁcant effect of pharmacological treatment
as detected by 2-way-RM ANOVA, xSigniﬁcant effect of GDAP1 silencing as detected by
2-way-RM ANOVA.
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Figure 4: GDAP1 silencing reduces lipid oxidation without affecting glucose metabolism. Primary human skeletal muscle cells were used to assess lipid oxidation and
glucose metabolism. Cells were transfected with a non-targeting scrambled control RNA (open squares) or siRNA targeted against GDAP1 (black circles). (A) Lipid oxidation in the
presence of 0e5 g/L glucose. (B) Glucose oxidation in the absence or presence of 10 or 120 nM insulin. (C) Glycogen synthesis in the absence or presence of 10 or 120 nM insulin.
(D) Lactate production. (E) Glucose uptake. In all panels, data were normalized to protein content, and all data are plotted for n ¼ 7 matched samples. *Signiﬁcant pairwise
difference between subsets of data indicated by brackets as detected by pairwise post hoc tests after FDR-correction. ySigniﬁcant interaction between treatment dose and GDAP1
silencing as detected by 2-way-RM ANOVA. zSigniﬁcant effect of treatment dose as detected by 2-way-RM ANOVA.An unexpected discovery is that both GDAP1 silencing and AMPK
agonists alter the expression of several genes which are canonically
associated with the circadian rhythm. Primary human skeletal muscle
cells can be synchronized via serum-shock or serum-starvation pro-
tocols [53] and are therefore a useful model to study circadian biology.
The effects of GDAP1 silencing on the circadian machinery are
apparently robust, since we observed consistent changes in NPAS2MOLECULAR METABOLISM 16 (2018) 12e23  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comand DBP, despite the fact that the cells used in our studies were not
synchronized. The link between GDAP1 and circadian gene expression
is unknown. Because NPAS2 and DBP are antiphase to one another
[54], our ﬁnding that these genes are regulated in opposing directions
due to GDAP1 silencing is not surprising. Since DBP expression is
elevated in liver of mice subjected to diet-induced obesity [55], the
decrease due to GDAP1 silencing may be beneﬁcial for metaboliccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 19
Figure 5: GDAP1 silencing reduces non-mitochondrial respiration. Primary human skeletal muscle cells were used in a Mito Stress Test after being transfected with a non-
targeting scrambled control RNA (open squares) or siRNA targeted against GDAP1 (black circles). (A) Relative oxygen consumption rate are shown, and vertical dashed lines
represent sequential injections of oligomycin, then FCCP, and ﬁnally rotenone þ antimycin A. (B) Relative extracellular consumption rate (C) Non-mitochondrial respiration. (D) Basal
respiration. (E) ATP production. (F) Proton leak. (G) Maximal respiration. (H) Spare capacity. (I) Coupling efﬁciency. (J) Non-glycolytic acidiﬁcation. (K) Glycolytic capacity. All data
were normalized to protein content. Mean  SEM (AeB) or all individual responses (CeH) are plotted as relative rates from n ¼ 5 matched samples. *Signiﬁcant pairwise
difference between subsets of data indicated by brackets as detected by paired-t test. ySigniﬁcant differences among groups as detected by Friedman’s test (assumptions for 2-
way-RM ANOVA were not met).
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Table 3 e Mitochondrial morphology.
Mitochondrial Analysis Treatment Relative Value (AU) SEM
Mean Branch Length SCR 10.99 0.7718
Mean Branch Length siGDAP1 11.64 0.3837
Mean Branch Length NT 11.45 0.995
Median Branch Length SCR 8.938 0.4427
Median Branch Length siGDAP1 9.453 0.1862
Median Branch Length NT 9.214 0.638
Mean Network Size (Branches) SCR 52.58 7.206
Mean Network Size (Branches) siGDAP1 50.4 3.164
Mean Network Size (Branches) NT 50.76 1.472
Median Network Size (Branches) SCR 4.417 0.4167
Median Network Size (Branches) siGDAP1 5.042 0.2083
Median Network Size (Branches) NT 3.75 0.25
Networks SCR 60 18.33
Networks siGDAP1 42.29 0.9583
Networks NT 61 7.333
Mitochondrial morphology was examined using confocal microscopy (LSM880. Carl
Zeiss AG. Jena, Germany) after staining cells with ViaFluor SE (Biotium Inc., Fremont.
CA), Hoechst dye, and MitoTracker Deep Red (Thermo Fisher Scientiﬁc), according to
manufacturer’s instructions. Images from elongated multinucleated cells were
captured using a 40x-objective on a confocal microscope. Images were analyzed via
Mitochondrial Network Analysis (MiNA) toolset and ImageJ [22]. There were no
quantitative statistical differences between mitochondrial networks. SCR ¼ Scramble.
NT¼ Non-transfected, AU¼ Arbitrary units (relative), SEM¼ Standard Error of Mean.
Results are mean  SEM for N ¼ 3 with 3 images per subject per condition.
Figure 6: Mitochondrial networks in primary skeletal muscle are unaltered by
GDAP1 silencing. Primary human skeletal muscle cells were used for visualizing the
mitochondrial networks. Sample images are shown where the white indicates the
MitoTracker Deep Red dye. (A) Cells transfected with control RNA. (B) Cells transfected
with siRNA against GDAP1.regulation. NPAS2 can substitute for the CLOCK gene to code for a
protein capable of pairing with BMAL1 to induce transcription of other
genes [56]. Moreover, NPAS2 has a greater amplitude in skeletal
muscle circadian rhythm as compared to CLOCK [56]. Our ﬁndings of
increased NPAS2 expression in GDAP1-silenced cells strengthen the
case for further study of this AMPK-regulated target. We have previ-
ously reported an interaction between AMPK activity and other mo-
lecular components of the circadian clock [57], but this is the ﬁrst
evidence that AMPK agonists impact DBP, NR1D2, and PER3. It ap-
pears that in cultured primary human skeletal muscle cells, GDAP1 is
not circadian per se. However, the circadian clock is has multiple
feedback loops, both positive and negative, ranging from an intracel-
lular, to a systemic level. Our discoveries regarding the ability of AMPK
agonists and GDAP1 silencing to alter core components of the circa-
dian clock has major implications for the role of these genes in pre-
serving metabolic health.MOLECULAR METABOLISM 16 (2018) 12e23  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comIn conclusion, using publically available microarray data, we identiﬁed
several novel AMPK-regulated genes including GDAP1. Other AMPK-
regulated candidate genes eAAMDC, ASPH, DPP8, KANSL1L, and
LPIN1e warrant future research. We reveal a role for GDAP1 in
modulating mitochondrial protein abundance, lipid oxidation, and non-
mitochondrial respiration. In the absence of direct evidence for a role of
GDAP1 in modulating mitochondrial function, we suggest that it plays a
role in maintaining peroxisomal integrity in skeletal muscle. We also
report GDAP1 silencing and AMPK agonists interact in a previously
undescribed manner to alter the expression of key molecular com-
ponents of the core circadian clock machinery. Collectively, our results
highlight a role for GDAP1 in the regulation of metabolic processes and
circadian gene expression in skeletal muscle.
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